Clinical Trials · NCT04639414

Combined Active Treatment in Type 2 Diabetes With NASH

CompletedPhase 4Semaglutide (Approved)
Phase
Phase 4
Recruitment status
Completed
Sponsor
German Diabetes Center
Enrollment
192
Start date
Mar 2021
Locations
26 sites, Austria, Germany
Primary endpoint
Histological resolution of NASH without worsening of fibrosis
View Semaglutide compound reference